Supernus CFO awarded performance share units

SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units.

Accepted by SEC EDGAR 03/03/2026 - 04:11 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units. On the reported transaction date, 3,000 performance share units were credited to his direct holdings at no exercise price. According to a footnote, these units were originally awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives established on June 24, 2024.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 2 txns

Insider DEC TIMOTHY C

Role Senior Vice-President & CFO

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit	3,000	$0.00	$0.00
Grant/Award	Performance Share Unit	3,000	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 6,000 contracts (Direct)

Holdings Before and After: Performance Share Unit, 0 to 6,000 contracts (Direct)

Footnotes (1)

1. F1. On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SUPN report for Timothy C. Dec?

SUPN reported that Senior Vice-President & CFO Timothy C. Dec acquired 3,000 performance share units. These derivative securities were credited at a price of $0.00 per unit and are held directly in his name as reflected after the reported transaction.

What type of security did the SUPN Form 4 transaction involve?

The Form 4 transaction for SUPN involved Performance Share Units, a type of derivative security. These units were granted at no cash cost and are linked to performance criteria rather than open-market share purchases or sales by the executive.

When were Timothy C. Dec’s performance share units originally awarded at SUPN?

The performance share units were originally awarded on February 22, 2024. A footnote explains that a portion of this award vested after individual performance objectives were achieved within a defined period, with those objectives formally established on June 24, 2024.

What performance conditions applied to SUPN CFO Timothy C. Dec’s units?

The award included individual performance objectives that had to be achieved within a defined performance period. These objectives were established on June 24, 2024, and a portion of the performance share units vested once those objectives were met, leading to the reported acquisition.

Does the SUPN Form 4 show a market purchase or sale by the CFO?

No, the Form 4 shows an acquisition coded as a grant or award, not a market trade. The 3,000 performance share units were credited at a price of $0.00 per unit, reflecting equity compensation tied to performance rather than a buy or sell in the open market.

How many performance share units does Timothy C. Dec hold after the SUPN transaction?

After the reported transaction, Timothy C. Dec directly holds 3,000 performance share units. This total reflects the credited award linked to previously established performance objectives, as disclosed in the Form 4 and its accompanying footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEC TIMOTHY C

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice-President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	02/28/2026		A		3,000		(1)	(1)	Common Stock	3,000	$0	3,000	D
Performance Share Unit	$0	02/28/2026		A		3,000		(1)	(1)	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

Remarks:

	/s/ Timothy C. Dec	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.